Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation.

Clinical cancer research : an official journal of the American Association for Cancer Research - 3 Jun 2024

Rolfo Christian D, Madison Russell W, Pasquina Lincoln W, Brown Derek W, Huang Yanmei, Hughes Jason D, Graf Ryon P, Oxnard Geoffrey R, Husain Hatim

Abstract excerpt

PURPOSE: Liquid biopsy (LBx) for tumor profiling is increasingly used, but concerns remain regarding negative results. A lack of results may truly reflect tumor genomics, or it may be a false negative that would be clarified by tissue testing. A method of distinguishing between these scenarios could help clarify when follow-on tissue testing is valuable. EXPERIMENTAL DESIGN: Here we evaluate circulating tumor DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Liquid Biopsy
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Genomics

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38526394
DOI: 10.1158/1078-0432.CCR-23-3321
PMCID: PMC11145175

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation.PMID 38526394Read ↗

Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.Semantic proximity Read ↗

Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.Semantic proximity Read ↗

Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA SamplesSemantic proximity Read ↗

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung CancersSemantic proximity Read ↗

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study.Semantic proximity Read ↗

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNASemantic proximity Read ↗

Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.Semantic proximity Read ↗

Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancerSemantic proximity Read ↗

A clinician's handbook for using ctDNA throughout the patient journey.Semantic proximity Read ↗

Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer TypesSemantic proximity Read ↗

Liquid biopsies across the cancer care continuum.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.